Clinical Trials for Non-Small Cell Lung Cancer

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with previously treated, locally advanced or metastatic, HER2 IHC 3+ solid tumors (excluding biliary tract cancers) who have progressed after at least one prior systemic therapy and lack standard treatment options; patients receive zanidatamab, a bispecific antibody targeting two HER2 epitopes. Eligible patients must have measurable disease, ECOG 0–1, and no active CNS metastases.

ClinicalTrials.gov ID: NCT06695845

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors harboring homozygous MTAP deletion receive oral MRTX1719 (BMS-986504), an investigational inhibitor of the PRMT5–MTA complex. Selected tumor types may receive MRTX1719 with standard-of-care therapy in a sub-study.

ClinicalTrials.gov ID: NCT05245500

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic EGFR-mutant NSCLC who progressed after at least four months of benefit from osimertinib receive osimertinib plus intravenous quaratusugene ozeplasmid, a lipid-nanoparticle gene therapy delivering the TUSC2 tumor suppressor. The randomized portion compares this combination with platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT04486833

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with metastatic KRAS G12C-mutated NSCLC and untreated brain metastases (up to 10 lesions, none >3 cm), who are either treatment-naïve or have received up to two prior lines of therapy, to receive combination therapy with the selective KRAS G12C inhibitor adagrasib plus stereotactic radiosurgery. Prior KRAS G12C inhibitor therapy is not allowed.

ClinicalTrials.gov ID: NCT06248606

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, progressive advanced solid tumors and no suitable standard therapy receive GV20-0251 alone or with pembrolizumab; expansion cohorts focus on selected tumor types, including melanoma, NSCLC, head and neck and endometrial cancers, and pMMR/MSS colorectal cancer in combination cohorts. GV20-0251 is an investigational antibody targeting IGSF8, a proposed innate immune checkpoint.

ClinicalTrials.gov ID: NCT05669430

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls treatment-naive adults with advanced nonsquamous NSCLC that is KRAS p.G12C positive and PD-L1 negative, randomizing them to receive either sotorasib (a KRAS G12C inhibitor) plus carboplatin/pemetrexed or pembrolizumab plus carboplatin/pemetrexed.

ClinicalTrials.gov ID: NCT05920356

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic ER-positive/HER2-negative breast cancer after endocrine therapy and a CDK4/6 inhibitor are the main population; monotherapy dose escalation also includes castration-resistant prostate cancer and non-small cell lung cancer. The study tests oral PF-07248144, a KAT6A/KAT6B histone acetyltransferase inhibitor, alone or with fulvestrant, letrozole plus palbociclib, or fulvestrant plus the selective CDK4 inhibitor atirmociclib.

ClinicalTrials.gov ID: NCT04606446

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, unresectable advanced or metastatic solid tumors and ECOG performance status 0–1 receive intravenous DB-1311/BNT324 every 21 days in dose-escalation or tumor-specific expansion cohorts. DB-1311/BNT324 is an investigational B7-H3–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload; prior B7-H3–targeted therapy or a topoisomerase inhibitor–payload ADC is excluded.

ClinicalTrials.gov ID: NCT05914116

A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with stage IV or recurrent NSCLC with MET amplification (as detected by tissue NGS) who have progressed on at least one prior systemic therapy and have not received MET TKIs or have other actionable mutations are eligible to receive subcutaneous amivantamab, a bispecific antibody targeting EGFR and MET. All participants receive this investigational agent until progression or toxicity.

ClinicalTrials.gov ID: NCT06116682

Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with stage IV NSCLC who have progressed on first-line immunotherapy or chemoimmunotherapy receive a single fraction of spatially fractionated grid radiotherapy to a selected extracranial tumor lesion, followed by five fractions of palliative radiation and continuation of standard immunotherapy. Eligible patients must have at least one lesion ≥3 cm suitable for grid therapy and ECOG 0–2, with controlled brain metastases allowed.

ClinicalTrials.gov ID: NCT06660407